Alogliptin CAS NO.850649-61-5

Shandong Luning Pharmaceutical Co., Ltd. was established in 2012. Covering an area of 80000 square meters, the company has solid preparation workshop, synthetic raw material workshop, drug R & D and testing center and complete supporting facilities. It has passed ISO9001, ISO14000 and new GMP certification, and established a municipal key laboratory, which is a modern enterprise in line with the pharmaceutical industry norms.

Focusing on the development and production of APIs and preparations as well as new energy and new materials, the existing products of the company include Gentamycin Sulfate Granules, Lysozyme Buccal Tablets, Heparin Sodium Buccal Tabletes, Sulfmethoxazole, Trimethoprim, Boneol and Artificial Cow-bezoar Tablets, Alogliptin, Tadalafil, Azilsartan, Agomelatine, Vitamin B6, Lipoic Acid and its intermediates, Ethyl 6,8-dichlorooctanoate, Dapoxetine Hydrochloride, Sildenafil Citrate, Cetilistat, D-Cycloserine, (1R,3R)-9H-pyrido[3,4-B]indole-3-carboxylic acid, 1,2,3,4-tetrahydro-1-(3,4-methylenedioxyphenyl), methyl ester, hydrochloride, Methylcyclopentadienyl Manganese Tricarbonyl, Dicyclopentadiene, Isoprene, Iso-Propyl Alcohol, Acetonitrile, etc.

"Independent R & D and strategic cooperation" is the guarantee for better and faster development of Luning. The company develops innovative drugs with Chinese Academy of Sciences, Shanghai Jiao Tong University, School of Pharmaceutical Sciences of Shandong University, Tsinghua University doctoral team and other universities and scientific research institutions. The innovative drugs relate to the fields of anti-tumor, anti-depression, cardio cerebrovascular, hypoglycemic, improving immunity, new energy, etc. It is worth mentioning that Luning has cooperated with Academician Yan Deyue of Shanghai Jiao Tong University to set up academician workstation and jointly developed the innovative drug - Nano targeted anti-tumor drug (MTS). The pharmaceutical technology has made a significant breakthrough, and the innovative drug will completely change the safety and drug resistance of anti-tumor drug treatment.

The company is committed to the big health industry, and will build an industrial cluster mainly composed of pharmaceuticals, health products, high-end medical devices, new energy and new materials, striving to become a company with unique competitive advantages and make contributions to human health.